Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

This research study will test the safety and anticancer activity of the combination of three drugs (Roginolisib, Venetoclax, and Rituximab) for participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL). The names of the study drugs involved in this study are: * Roginolisib (a novel type of PI3-kinase delta inhibitor) * Venetoclax (a type of B-cell lymphoma 2 inhibitor) * Rituximab (a type of monoclonal antibody)

Trial Details

NCT ID
NCT06644183
Phase
PHASE1 / PHASE2
Sponsor
Jennifer R. Brown, MD, PhD
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Roginolisib
  • Venetoclax
  • Rituximab
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Patients with relapsed/refractory CLL who meet iwCLL criteria for requiring treatment.
  • Patients with measurable disease as defined by at least one of: circulating lymphocytosis \> 5000 B cells/microliter, bone marrow involvement \> 30…
  • Patients must have received at least two prior therapies for CLL including systemic therapy containing a covalent BTK inhibitor.
  • Patients willing to undergo a pre-treatment and on treatment bone marrow biopsy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →